Press Release


Emeryville, California, March 3, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that the company is scheduled to present at the following March healthcare conferences:


Cowen 40th Annual Health Care Conference

Title:                 ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors

Speaker:          Hanzhong Li, Ph.D., Senior Vice President of Corporate Strategy

Location:         Boston Marriott Copley Place, Boston, MA

Date:                 Wednesday, March 4, 2020

Time:                 8:30 a.m. EST


BioProcess International US West

Title:                 Optimizing Viral Vector Production

Speaker:          Nicole Nunez, Ph.D., Process Development Scientist

Location:         Santa Clara Convention Center, Santa Clara, CA

Date:                 Wednesday, March 11, 2020

Time:                 1:05 p.m. PST


About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® AbTCR T cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit



Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations

KKH Advisors
Kimberly Ha